Using A Natural History Study As An External Control In Rare Diseases: Ipsen Offers An Example

Although the advisory committee was uncomfortable with the external control, US FDA was reassuring over the approach – which eventually secured a ‘yes’ vote from the panel on palovarotene for FOP.